| Expression pattern: |
UP |
| Associated gene: |
BCR-ABL, ABL, AGO2, Wnt/beta-catenin signaling pathway, CTNNB1, c-Myc |
| Associated microRNA: |
miR-877-5p |
| Biological function: |
promotes CML cell proliferation; promotes malignant progression in vivo; augments susceptibility of resistant cells to imatinib when knocked down |
| Molecular mechanism: |
ceRNA/miRNA sponge: circCRKL sponges miR-877-5p to increase BCR-ABL (ABL) mRNA/protein; involves AGO2-containing RISC |
| Biological pathway or process: |
proliferation (promotes); cell cycle (promotes); apoptosis (inhibits); ceRNA regulation (promotes); Wnt/beta-catenin (promotes); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Sanger Sequencing; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Transfection; CCK8; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Luciferase Reporter Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); Western Blot; IF (Immunofluorescence); In Vivo Animal Model; H&E Staining; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
- |
| Description: |
circCRKL is up-regulated in CML (especially BCR-ABL+ cells) and predominantly localizes to the cytoplasm. It promotes CML proliferation by sponging miR-877-5p in an AGO2-associated manner, thereby increasing BCR-ABL/ABL expression; circCRKL knockdown also increases imatinib sensitivity, potentially involving Wnt/beta-catenin signaling changes. |
| Confidence score: |
0.8491 |